Thai Breast Disease Society

30/12/2025

For patients with LN-negative Invasive papillary breast cancer with tumor ≥ 2.0 cm and patients with grade III or undifferentiated disease, chemotherapy significantly improved OS. Future randomized controlled trials are expected to validate the results.

AbstractBackground. Invasive papillary breast cancer (IPC) is a rare cancer known to have a better prognosis than other breast cancers. This study aimed to

23/12/2025

Both real and sham acupuncture improve breast cancer survivors’ perceived cognitive impairment more effectively than usual care alone, while real acupuncture improves objective measures of cognitive performance better than sham acupuncture: ENHANCE trial: 2025 SABCS UPDATE

23/12/2025

Using menopausal hormone therapy was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched prospective analysis: 2025 SABCS UPDATE

23/12/2025

RAD51-low status strongly predicts benefit from olaparib in HER2-negative metastatic breast cancer, refining PARP inhibitor selection beyond BRCA mutations alone: RADIOLA trial: 2025 SABCS UPDATE

23/12/2025

Gedatolisib combinations may redefine second-line therapy after CDK4/6i in PIK3CA-WT HR+/HER2- metastatic breast cancer: VIKTORIA-1 trial: 2025 SABCS UPDATE

23/12/2025

Abemaciclib + endocrine therapy outperforms chemotherapy for first-line treatment of high-burden HR+/HER2- metastatic disease: AMBRE trial: 2025 SABCS UPDATE

23/12/2025

T-DXd + pertuzumab delivers first-line efficacy gains with preserved quality of life and a predictable, manageable symptom profile: DESTINY-Breast09 trial: 2025 SABCS UPDATE

23/12/2025

Palbociclib may meaningfully delay or prevent CNS metastases when added to anti-HER2/endocrine maintenance therapy in HR+/HER2+ MBC: PATINA trial: 2025 SABCS UPDATE

23/12/2025

For postoperative high risk TNBC, adding carboplatin to ddEC plus weekly paclitaxel delivers a meaningful DFS and OS advantage: CITRINE trial: 2025 SABCS UPDATE

23/12/2025

Adding carboplatin to standard adjuvant chemotherapy significantly improves survival in early TNBC despite increased hematologic toxicity: RJBC 1501 trial: 2025 SABCS UPDATE

https://ascopubs.org/doi/full/10.1200/JCO-25-02412

23/12/2025

sacituzumab govitecan delivers better quality of life and faster symptom improvement than chemotherapy in first-line advanced TNBC without immunotherapy options: ASCENT-03 trial: 2025 SABCS UPDATE

23/12/2025

Post-surgery ctDNA positivity is one of the strongest known predictors of recurrence in early TNBC: GeparDouze trial: 2025 SABCS UPDATE